Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters.
Mr. Cable represents buyers, sellers and investment banks in his M&A practice. Representative M&A transactions in the past five years include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the 2015 majority sale of Foundation Medicine to Roche ($1 billion) and the subsequent (2018) negotiated tender for the public stub by Roche ($2.4 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the acquisition of NXP by Qualcomm ($47 billion), the Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion), the cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals, the sale of Neustar to Golden Gate ($2.9 billion), the sale of Lionbridge to HIG ($400 million), the sale of AMRI to Carlyle and GTCR ($1.9 billion), the sale of PAREXEL to Pamplona ($5 billion), the cross border sale of inviCRO to Konica Minolta (Japan) ($300 million), the merger of equals transaction between Keryx and Akebia ($1 billion) and the acquisition of Civitas by Centerbridge ($1.4 billion).
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors, most recently representing the independent committee of Sprint in the 2018 Sprint/T-Mobile transaction ($26 billion). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions.
Mr. Cable serves regularly as counsel to issuers in IPOs, most recently representing Moderna and Rubius in their record setting IPOs in the biotechnology industry. Mr. Cable also represents underwriters in such transactions, including Morgan Stanley, JPM and Citi.
Mr. Cable also represents tech and life sciences companies in complex minority strategic transactions including KIND in its 2018 partnership with Mars, Cornerstone onDemand in its 2018 $300 million convertible debt PIPE with Silver Lake and Microsoft, and PTC in its 2018 $1 billion common stock PIPE and strategic partnership with Rockwell.
Mr. Cable periodically represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliott Management on behalf of Cognizant and Citrix.
Mr. Cable represents a number of private venture backed life sciences companies in Board governance, collaboration transactions, crossover financings and capital market transactions (including Moderna, Rubius, Ohana and Yumanity).
